The project´s outcome will be a potential solution that simultaneously combines the benefits of Tada Medical AB´s breakaway connector ReLink, that prevents IV catheter failure, with Amicoat´s antimicrobial peptide AMC-109 which prevents growth of bacteria and fungi (also when they occur in biofilms) and viruses.
The two-year collaborative project will combine two patented technologies to develop a family of breakaway connectors with antimicrobial properties. These can be adapted for therapies ranging from rapid blood transfusion, dialysis, treatment of large animals to those requiring central venous catheters, neonatal care and insulin pumps.
As an outcome, we intend to commercialise this technology and deliver significant value to healthcare providers globally.
留言